Merck's $6.7 Billion Tern Acquisition Faces Investor Scrutiny
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy TERN?
Source: seekingalpha
- Acquisition Premium Concerns: Merck's acquisition of Tern Pharmaceuticals for $6.7 billion at $53 per share represents only a 6% premium, raising investor concerns about whether this premium is adequate for a high-probability asset, suggesting a lack of confidence from both Merck and Tern in the drug's potential.
- Investor Reactions: RBC analyst Trung Huynh noted that while some investors defend the $6.7 billion price as reasonable, there is a mixed market response, with expectations of competing bids or shareholder rejection of the deal.
- Market Expectations: Tern's stock had already surged 25% prior to the deal announcement, which somewhat mitigates the perception of a weak premium, indicating that the market recognizes the asset's potential value.
- Future Developments: RBC anticipates the release of a 14D-9 document early next month, which will provide more details about the transaction, and investors are adopting a wait-and-see approach, looking for potential competitive bids in the future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TERN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TERN
Wall Street analysts forecast TERN stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 53.170
Low
35.00
Averages
54.22
High
60.00
Current: 53.170
Low
35.00
Averages
54.22
High
60.00
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
A Guide to Participating in the SpaceX IPO
SpaceX IPO Plans: SpaceX is anticipated to file for an initial public offering later this year, signaling a potential growth opportunity for investors.
Investor Interest: Investors are actively seeking to purchase funds that hold pre-IPO shares of SpaceX, aiming to benefit from the company's expected boom.
Caution Advised: Potential buyers are warned to exercise caution when investing in pre-IPO shares, as risks may be involved.
Elon Musk's Ventures: The interest in SpaceX is tied to Elon Musk's broader ventures in rockets, satellites, and artificial intelligence, which are seen as promising sectors.
See More
Novartis Plans $2 Billion Acquisition of Excellergy for Allergy Treatment
- Acquisition Strategy: Novartis is planning to acquire U.S.-based biotech Excellergy for up to $2 billion, aiming to enhance its allergy drug portfolio by introducing the early-stage candidate Exl-111, which is expected to outperform existing market treatments in speed and efficacy.
- Patent Expiration Response: This acquisition represents Novartis' latest bolt-on deal to counteract looming patent expirations, particularly as its best-selling drugs face generic competition, which is anticipated to positively impact future revenue streams.
- Recent Transaction Activity: Prior to the Excellergy deal, Novartis announced the acquisition of Pikavation Therapeutics for up to $3 billion to secure rights to an experimental breast cancer drug, highlighting its strategic focus on oncology.
- Market Reaction: While Novartis shares traded sideways in morning trading in Zurich, they have increased by 33% over the past year, reflecting market confidence in its acquisition strategy and future growth potential.
See More
Merck Included in 15 Dividend Stocks for Income Investment
- Rating Reaffirmed: On March 25, RBC reiterated its Outperform rating on Merck & Co., Inc. (NYSE:MRK) with a price target of $142, indicating confidence in the company's future performance despite investor disappointment over the 'modest premium' for the acquisition of Terns Pharmaceuticals.
- Acquisition Feedback Analysis: Following a conference call discussing the proposed acquisition of Terns, RBC analyst Trung Huynh noted that investor feedback was largely negative, questioning why Terns would agree to sell a high-probability asset at what was described as a 'modest premium', reflecting market caution regarding the deal.
- Capital Allocation Recognition: Despite concerns over the acquisition, investors still view Merck as a savvy capital allocator capable of effectively addressing its upcoming patent cliff, indicating that the company's strategic position in the industry remains recognized.
- Potential Competitive Threats: There is an expectation that competing bidders may emerge or that shareholders could outright reject the deal, which could impact Merck's stock performance, necessitating close monitoring of subsequent developments.
See More
Halper Sadeh LLC Investigates Multiple Companies for Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Terns Pharmaceuticals, Inc. (NASDAQ:TERN) regarding its sale to Merck for $53.00 per share, which may involve potential violations of shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: The merger between Corebridge Financial, Inc. (NYSE:CRBG) and Equitable Holdings, Inc. will result in Corebridge shareholders owning approximately 51% of the combined entity, with the law firm potentially seeking increased compensation and disclosures for shareholders.
- Equitable Shareholder Rights: Equitable Holdings, Inc. (NYSE:EQH) shareholders will own about 49% of the combined company post-merger with Corebridge, and Halper Sadeh LLC encourages shareholders to learn about their legal rights and options to protect their interests.
- Legal Service Commitment: The firm commits to providing legal services on a contingency fee basis, ensuring affected investors can seek legal remedies without upfront financial burdens.
See More
Merck's Acquisition Sparks Interest in Blood Cancer Drug Market
- Acquisition Premium Analysis: Merck's acquisition of Terns at $53 per share represents a 42% premium, which not only strengthens its blood cancer pipeline but also raises market interest in Sellas, potentially driving up its valuation.
- Investor Sentiment Shift: Following the Merck deal, retail investors are increasingly viewing Pfizer as a potential acquirer of Sellas, reflecting a growing interest in blood cancer drugs and potential M&A opportunities in the sector.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial has recorded 72 death events in AML patients, nearing the 80 required for final analysis, showcasing the clinical potential of its product and likely attracting more investor attention.
- Market Valuation Expectations: Retail investors estimate that Sellas' lead AML candidate, Galinpepimut-S, could be valued between $33.5 billion and $53.6 billion based on projected revenues, indicating optimistic market expectations for its future earnings and further driving demand for its stock.
See More
SLS Shares Surge Following Merck's Tern Acquisition, Fueling Buyout Speculation in Blood Cancer Sector: Retail Investors Eye Major Pharma Contender
Merck's Acquisition of Terns Pharmaceuticals: Merck is set to acquire Terns Pharmaceuticals for $6.7 billion, which includes a 42% premium for the mid-stage leukemia drug TERN-701, enhancing Merck's blood cancer pipeline.
Investor Sentiment Towards Pfizer: Retail investors are increasingly viewing Pfizer as a potential buyer following Merck's acquisition, with attention on Pfizer's ongoing clinical work in hematologic cancers and its need for growth drivers post-COVID.
Sellas Life Sciences Stock Surge: Shares of Sellas Life Sciences jumped over 6% after the announcement of Merck's acquisition, reflecting renewed interest in potential takeovers in the blood cancer drug market.
Focus on Clinical Trials: Investor focus remains on the Phase 3 trial of GPS in AML patients, with significant patient death events recorded, as the study aims to reach final analysis after 80 events, indicating the high stakes involved in these clinical evaluations.
See More
A Guide to Participating in the SpaceX IPO
SpaceX IPO Plans: SpaceX is anticipated to file for an initial public offering later this year, signaling a potential growth opportunity for investors.
Investor Interest: Investors are actively seeking to purchase funds that hold pre-IPO shares of SpaceX, aiming to benefit from the company's expected boom.
Caution Advised: Potential buyers are warned to exercise caution when investing in pre-IPO shares, as risks may be involved.
Elon Musk's Ventures: The interest in SpaceX is tied to Elon Musk's broader ventures in rockets, satellites, and artificial intelligence, which are seen as promising sectors.
See More
Novartis Plans $2 Billion Acquisition of Excellergy for Allergy Treatment
- Acquisition Strategy: Novartis is planning to acquire U.S.-based biotech Excellergy for up to $2 billion, aiming to enhance its allergy drug portfolio by introducing the early-stage candidate Exl-111, which is expected to outperform existing market treatments in speed and efficacy.
- Patent Expiration Response: This acquisition represents Novartis' latest bolt-on deal to counteract looming patent expirations, particularly as its best-selling drugs face generic competition, which is anticipated to positively impact future revenue streams.
- Recent Transaction Activity: Prior to the Excellergy deal, Novartis announced the acquisition of Pikavation Therapeutics for up to $3 billion to secure rights to an experimental breast cancer drug, highlighting its strategic focus on oncology.
- Market Reaction: While Novartis shares traded sideways in morning trading in Zurich, they have increased by 33% over the past year, reflecting market confidence in its acquisition strategy and future growth potential.
See More
Merck Included in 15 Dividend Stocks for Income Investment
- Rating Reaffirmed: On March 25, RBC reiterated its Outperform rating on Merck & Co., Inc. (NYSE:MRK) with a price target of $142, indicating confidence in the company's future performance despite investor disappointment over the 'modest premium' for the acquisition of Terns Pharmaceuticals.
- Acquisition Feedback Analysis: Following a conference call discussing the proposed acquisition of Terns, RBC analyst Trung Huynh noted that investor feedback was largely negative, questioning why Terns would agree to sell a high-probability asset at what was described as a 'modest premium', reflecting market caution regarding the deal.
- Capital Allocation Recognition: Despite concerns over the acquisition, investors still view Merck as a savvy capital allocator capable of effectively addressing its upcoming patent cliff, indicating that the company's strategic position in the industry remains recognized.
- Potential Competitive Threats: There is an expectation that competing bidders may emerge or that shareholders could outright reject the deal, which could impact Merck's stock performance, necessitating close monitoring of subsequent developments.
See More
Halper Sadeh LLC Investigates Multiple Companies for Potential Violations
- Shareholder Rights Investigation: Halper Sadeh LLC is investigating Terns Pharmaceuticals, Inc. (NASDAQ:TERN) regarding its sale to Merck for $53.00 per share, which may involve potential violations of shareholder rights, prompting shareholders to understand their rights and options.
- Merger Transaction Review: The merger between Corebridge Financial, Inc. (NYSE:CRBG) and Equitable Holdings, Inc. will result in Corebridge shareholders owning approximately 51% of the combined entity, with the law firm potentially seeking increased compensation and disclosures for shareholders.
- Equitable Shareholder Rights: Equitable Holdings, Inc. (NYSE:EQH) shareholders will own about 49% of the combined company post-merger with Corebridge, and Halper Sadeh LLC encourages shareholders to learn about their legal rights and options to protect their interests.
- Legal Service Commitment: The firm commits to providing legal services on a contingency fee basis, ensuring affected investors can seek legal remedies without upfront financial burdens.
See More
Merck's Acquisition Sparks Interest in Blood Cancer Drug Market
- Acquisition Premium Analysis: Merck's acquisition of Terns at $53 per share represents a 42% premium, which not only strengthens its blood cancer pipeline but also raises market interest in Sellas, potentially driving up its valuation.
- Investor Sentiment Shift: Following the Merck deal, retail investors are increasingly viewing Pfizer as a potential acquirer of Sellas, reflecting a growing interest in blood cancer drugs and potential M&A opportunities in the sector.
- Clinical Trial Progress: Sellas' Phase 3 Regal trial has recorded 72 death events in AML patients, nearing the 80 required for final analysis, showcasing the clinical potential of its product and likely attracting more investor attention.
- Market Valuation Expectations: Retail investors estimate that Sellas' lead AML candidate, Galinpepimut-S, could be valued between $33.5 billion and $53.6 billion based on projected revenues, indicating optimistic market expectations for its future earnings and further driving demand for its stock.
See More
SLS Shares Surge Following Merck's Tern Acquisition, Fueling Buyout Speculation in Blood Cancer Sector: Retail Investors Eye Major Pharma Contender
Merck's Acquisition of Terns Pharmaceuticals: Merck is set to acquire Terns Pharmaceuticals for $6.7 billion, which includes a 42% premium for the mid-stage leukemia drug TERN-701, enhancing Merck's blood cancer pipeline.
Investor Sentiment Towards Pfizer: Retail investors are increasingly viewing Pfizer as a potential buyer following Merck's acquisition, with attention on Pfizer's ongoing clinical work in hematologic cancers and its need for growth drivers post-COVID.
Sellas Life Sciences Stock Surge: Shares of Sellas Life Sciences jumped over 6% after the announcement of Merck's acquisition, reflecting renewed interest in potential takeovers in the blood cancer drug market.
Focus on Clinical Trials: Investor focus remains on the Phase 3 trial of GPS in AML patients, with significant patient death events recorded, as the study aims to reach final analysis after 80 events, indicating the high stakes involved in these clinical evaluations.
See More
